Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule.
Abnormal coagulation studies indicative of a dysfibrinogen were found in the plasma of four of seven patients with malignant hepatoma. The abnormal fibrinogen was characterized by prolonged prothrombin, thrombin and reptilase times and inhibition of the coagulation of normal plasma. Purified fibrinogen revealed abnormalities similar to those in plasma. The functional defect was one of delayed polymerization of the fibrin monomer. The carbohydrate content of the abnormal fibrinogen was increased, and this change was related to the abnormal fibrinogen function. Enzymatic cleavage of sialic acid from the abnormal fibrinogen restored fibrinogen function to normal. This hepatoma-associated dysfibrinogen (acquired dysfibrinogenemia) is similar in many respects to fetal fibrinogen and may represent the presence of a fetal form of fibrinogen in hepatoma.
D001778:Blood Coagulation Disorders / Q000209:etiology*; D001780:Blood Coagulation Tests; D002241:Carbohydrates / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000150:complications; D005312:Fetal Blood / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood* / Q000150:complications; D009439:Neuraminidase / Q000494:pharmacology; D012794:Sialic Acids / Q000097:blood
D002241:Carbohydrates; D012794:Sialic Acids; D005340:Fibrinogen; D009439:Neuraminidase